You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK):降糖藥卡格列淨片獲批上市
格隆匯 12-24 15:13

格隆匯12月24日丨翰森製藥(03692.HK)宣佈,由公司附屬公司江蘇豪森藥業集團有限公司開發的"卡格列淨片"已獲中國國家藥品監督管理局頒發藥品註冊批件。卡格列淨片獲批上市,成為中國首仿的鈉-葡萄糖協同轉運蛋白2(SGLT-2)抑制劑,用於II型糖尿病患者。

卡格列淨片通過抑制腎小管對葡萄糖的重吸收而降低血液中的葡萄糖水平,從而達到治療II型糖尿病患者的作用,該藥物又因不依賴胰島素的分泌與作用水準,對各階段的II型糖尿病患者均有治療效果。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account